Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of pimavanserin tartrate capsules for hallucinations and delusions associated with Parkinson's disease psychosis
CTR20261709Phase 3Active
- Sponsor
- Zhejiang Beston Pharmaceutical Technology
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pimavanserin in Parkinson's disease (PD), sponsored by Zhejiang Beston Pharmaceutical Technology. Started May 2026; status: active.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20261709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261709.